+3,202.9%
VIAV vs GSK
+953.1%
+2,249.8%
-99.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +11.2% | -2.7% | +13.9% | +12.5% |
| 7D | +11.3% | -4.2% | +15.5% | +13.4% |
| 30D | -1.0% | -7.5% | +6.5% | +2.2% |
| 3M | -20.5% | -3.3% | -17.2% | -20.6% |
| 6M | +39.0% | -9.3% | +48.3% | +43.1% |
| YTD | +117.5% | +1.6% | +115.9% | +110.4% |
| 1Y | +233.8% | +25.5% | +208.3% | +188.8% |
| 3Y | +295.4% | +49.3% | +246.1% | +199.8% |
| 5Y | +134.3% | +46.7% | +87.6% | +73.9% |
| 10Y | +398.7% | +76.8% | +321.9% | +227.4% |
| All | +3,202.9% | +953.1% | +2,249.8% | +1,046.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling